Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4995 - CDK12 – new breast and ovarian cancer predisposition gene in Tatar population?

Date

11 Sep 2017

Session

Poster display session

Presenters

Elena Shagimardanova

Citation

Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362

Authors

E. Shagimardanova1, O. Brovkina2, M. Gordiev3, R. Enikeev4, L. Shigapova1, D. Khodyrev2, O. Gusev1, A. Kedrova2, V. Kosiy2, A. Nikitin2

Author affiliations

  • 1 Extreme Biology Laboratory, Kazan Volga Region Federal University, 420008 - Kazan/RU
  • 2 Molecular Genetic Laboratory, Federal Research and Clinical Center, FMBA of Russia, 115682 - Moscow/RU
  • 3 Laboratory, Tatarstan Cancer Center, Kazan/RU
  • 4 Chemotherapy, Kazan Clinical Oncology Center, 420029 - Kazan/RU
More

Resources

Abstract 4995

Background

The development of hereditary ovarian and breast cancer (OC/BC) is often caused by genetic defects in the DNA repair system. However, the diagnostics in most medical centers of Russia includes PCR-based identification only the eight common mutations in BRCA1/2 for the Slavic population. Previously we established that patients of the Tatar population with OC/BC did not possess most of Slavic mutation and a significant part of the predisposition is due to other mutations in the genes of the homologous recombination (HR) system. The aim of this work is the analysis of the germline mutations in the HR genes.

Methods

The DNA from 175 blood samples from patients of the Volga District with hereditary OC/BC were analyzed by targeted NGS (Roche NimbleGen, Illumina MiSeq), the comparison groups included blood samples from patients of Slavic origin.

Results

62% of the detected pathogenic mutations were presented in the BRCA1/2 genes. The remaining mutations were found in other genes of the reparation system (HGMD Professional 2017.1 database). An unexpected finding was the detection of a germline splicing mutation c.1047-2A>G in CDK12 gene (Chr17(GRCh37):37627130A>G, NM_016507.3) in patients of Tatar origin (Table).Table:

201P CDK12 c.1047-2A>G frequency distribution

Subjects origin BC or OC Healthy controls
Tatar from Volga District 6/94 (6.4%) 0/32 (0%)
Non-Tatar from Volga District 1/81 (1.2%)
Slavic from Moscow 0/49 (0%) 0/284 (0%)
ExAC NFE 29/64446 (0.045%)
1000G 2/5006 (0.039%)

Mutation c.1047-2A>G is more common in patients with OC/BC in comparison with healthy controls (7/224 vs 0/316, p = 0.002, OR = 21.49, CI 95% = 1.22–377.25).

Conclusions

Gene CDK12 is one of the most frequently altered genes in serous ovarian cancers, but significance of CDK12 germline mutations in hereditary cancers remains to be defined. Its role in carcinogenesis of OC was established recently and CDK12 was not included in most NGS panels of HR genes. Our study demonstrates that CDK12 may be novel candidate gene for OC/BC genetic predisposition. Notably, frequency of CDK12 c.1047-2A>G (6.4%) mutation is comparable with frequency of founder-mutation BRCA1 5382insC (7.4%), that indicates its possible founder role in Tatar population.

Clinical trial identification

Legal entity responsible for the study

Tatarstan Cancer Center

Funding

Kazan (Volga Region) Federal University, Tatarstan Cancer Center

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.